TOPAMAX (topiramate) by Johnson & Johnson is cytochrome p450 3a4 inducers [moa]. First approved in 1996.
Drug data last refreshed 13h ago · AI intelligence enriched 1w ago
TOPAMAX (topiramate) is an oral small-molecule anticonvulsant approved in 1996 that works as a cytochrome P450 3A4 inducer. While originally indicated for seizure disorders, it has been widely used off-label for migraine prophylaxis and weight management. The drug's mechanism involves modulation of sodium channels and carbonic anhydrase inhibition, making it relevant across multiple therapeutic areas.
As LOE approaches, brand team focus shifts from growth initiatives to lifecycle extension and managed decline strategies, with likely reduced headcount and consolidation of commercial efforts.
Cytochrome P450 3A4 Inducers
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events in Adult Participants With Migraine
Adjunct Phentermine + Topiramate After Bariatric Surgery in 12-24 Year Olds
Head-to-head Study of Erenumab Against Topiramate in Patients With Episodic and Chronic Migraine
The Effect of Topiramate on Etonogestrel Concentrations in Contraceptive Implant Users
Cognitive Effects of Immediate Release Topiramate vs Extended Release Topiramate in Patients With Migraine
Worked on TOPAMAX at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moPositions on TOPAMAX teams are declining as the product enters LOE, offering limited career growth but valuable experience in mature-market management, generic competition strategy, and lifecycle extension tactics. Professionals should expect role consolidation, transition planning, and eventual reassignment to growth-stage assets within the J&J portfolio.